{"name":"Aerovance, Inc.","slug":"aerovance-inc","ticker":"","exchange":"","domain":"","description":"Aerovance, Inc. is a biopharmaceutical company focused on developing innovative treatments for respiratory diseases. The company's pipeline includes three drugs in Phase 2 clinical trials, with a strong emphasis on advancing therapies that address significant unmet medical needs.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"AER 001","genericName":"AER 001","slug":"aer-001","indication":"Severe asthma","status":"phase_2"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Aerovant","genericName":"Aerovant","slug":"aerovant","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"AER 001","genericName":"AER 001","slug":"aer-001","phase":"phase_2","mechanism":"AER 001 is an investigational monoclonal antibody targeting IL-13.","indications":["Severe asthma"],"catalyst":""},{"name":"Aerovant","genericName":"Aerovant","slug":"aerovant","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":2,"phaseCounts":{"phase_2":2},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}